Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress
A. Li Wan Po,
A. Li Wan Po
Centre for Evidence-Based Pharmacotherapy, Aston University, Birmingham, UK
Search for more papers by this authorA. Li Wan Po,
A. Li Wan Po
Centre for Evidence-Based Pharmacotherapy, Aston University, Birmingham, UK
Search for more papers by this authorA. Li Wan Po, Centre for Evidence-Based Pharmacotherapy, Aston University, Birmingham B4 7ET, UK. Tel.: 121 359 3611; fax: 121 359 4693; e-mail: [email protected]
References
- 1 National Institute for Health Care Management (2002) Changing Patterns of Pharmaceutical Innovation. Washington: NIHCM Foundation.
- 2 Köhler G, Milstein C (1975) Continuous cultures of fused secreting antibody of defined specificity. Nature, 256, 495–497.
- 3 Southern EM (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. Journal of Molecular Biology, 98, 503–517.
- 4 Huxley A (1932) Brave New World. London: Chatton and Windus Ltd.
- 5 Schwartz RS (2004) Paul Ehrlich's magic bullet. New England Journal of Medicine, 350, 1079–1080.
- 6 Ehrlich P (1908) Partial cell functions. Nobel Lecture, 11 December.
- 7
Miller RALR (1981). Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody.
Lancet, ii, 226–230.
10.1016/S0140-6736(81)90475-X Google Scholar
- 8 Cobbold SPWH (1984) Therapeutic potential of monovalent monoclonal antibodies. Nature, 308, 460–462.
- 9 Fleischmann R, Iqbal I, Nanseshwar P, Quinceno A (2002) Safety and efficacy of disease-modifying anti-rheumatic agents. Drug Safety, 25, 173–197.
- 10 Springer TA (2002) César Milstein (1927–2002). Science, 296, 1253.
- 11 Lander ESLL, Linton LM, Birren B et al. (2001) Initial sequencing and analysis of the human genome. Nature, 2001, 860–921.
- 12 Venter JCAM, Adams LD et al. (2001) The sequence of the human genome. Science, 291, 1304–1351.
- 13 Dulbecco R (1975) From molecular biology of oncogenic DNA viruses to cancer. Nobel Lecture.
- 14 Temin HM (1975) The DNA provirus hypothesis. Nobel Lecture.
- 15 Baltimore D (1975) Viruses, polymerases and cancer. Nobel Lecture.
- 16 Wright P (1975) Untoward effects associated with practolol administration: oculomucocutaneous syndrome. British Medical Journal, 1, 595–598.
- 17 Topol EJ (2004) Failing the public health – Rofecoxib, Merck, and the FDA. NEJM, 351, 1707–1709.
- 18 Rumke CL (1975) Implications of the statement: no side effects were observed. New England Journal of Medicine, 292, 372–373.
- 19 Greenspan A (2003) Monetary policy under uncertainty. Washington, DC: The Federal Reserve Board. ( http://www.federalreserve.gov/boarddocs/speeches/2003/20031002/accessed17December2004 ).
- 20 Valéry Paul (1945) Regards sur le monde actuel.Paris: Editions Flammarion.
- 21 Barondes SH (2003) Better than Prozac. New York: Oxford University Press.
- 22 Dronamraju KR (1995) Haldane's Daedalus Revisited. Oxford: Oxford University Press.
- 23 Ashworth J (2004) ‘You have got to give our folks the chance to become millionaires’. J-P Garnier Interview. London: The Times, 15 November, 48–49.
- 24 Dyson F (1995) Daedalus after seventy years. In: KR Dronamraju, ed. Haldane's Daedalus Revisited. Oxford University Press.
- 25 Aaron HJ, Schwartz WB (eds) (2004) Coping with Methuselah: The Impact of Molecular Biology on Medicine and Society. Washington: Brooklyn Institution Press.
- 26 Oeppen J, Vaupel JW (2002). Demography. Broken limits of life expectancy. Science, 296, 1029–1031.
- 27 Peeters ABJ, Willekens F, Mackenbach JP, Mamun AA, Bonneux L (2003) Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Annals of Internal Medicine, 138, 24–32.
